Ausgabe 1/2013
Inhalt (30 Artikel)
Anti-vascular endothelial growth factor therapy in the era of personalized medicine
Luis R. Féliz, Apostolia M. Tsimberidou
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Adriana Romiti, M. Christina Cox, Ida Sarcina, Roberta Di Rocco, Chiara D’Antonio, Viola Barucca, Paolo Marchetti
Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells
Min Shi, Bingxiang Lou, Jun Ji, Hailong Shi, Chenfei Zhou, Yingyan Yu, Bingya Liu, Zhenggang Zhu, Jun Zhang
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
S. Agelaki, E. Kontopodis, A. Kotsakis, V. Chandrinos, I. Bompolaki, Ζ. Zafeiriou, E. Papadimitraki, D. Stoltidis, K. Kalbakis, V. Georgoulias
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
Anthony El-Khoueiry, James A. Posey, Juan Ramón Castillo Ferrando, Smitha S. Krishnamurthi, Shariq Syed, Georgia Kollia, Ian Walters, Bruce S. Fischer, Eric Masson
Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study
Sandrine Lavau-Denes, P. Lacroix, A. Maubon, P. M. Preux, D. Genet, L. Vénat-Bouvet, J. L. Labourey, J. Martin, P. Slaouti, N. Tubiana-Mathieu
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors
R. Salazar, H. Cortés-Funes, E. Casado, B. Pardo, A. López-Martín, C. Cuadra, J. Tabernero, C. Coronado, M. García, A. Soto Matos-Pita, B. Miguel-Lillo, M. Cullell-Young, J. L. Iglesias Dios, L. Paz-Ares
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
Syma Iqbal, Heinz-Josef Lenz, David R. Gandara, Stephen I. Shibata, Susan Groshen, Timothy W. Synold, Edward M. Newman
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model
Rachel Grossman, Betty Tyler, Michelle A. Rudek, Eugene Kim, Patti Zadnik, Ursalan Khan, Jaishri O. Blakeley, Arvind P. Pathak, Henry Brem
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma
Lisa N. Abaid, John P. Micha, Mark A. Rettenmaier, John V. Brown, Alberto A. Mendivil, Katrina L. Lopez, Bram H. Goldstein
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
Ji-Won Kim, Jee Hyun Kim, Seock-Ah Im, Yu Jung Kim, Hye-Suk Han, Jin-Soo Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Yoon Kyung Jeon, Do-Youn Oh, Tae-You Kim, In Ae Park
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination
Lucio Tentori, Alessia Muzi, Annalisa Susanna Dorio, Susanna Dolci, Federica Campolo, Patrizia Vernole, Pedro Miguel Lacal, Françoise Praz, Grazia Graziani
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues
Krupa J. Patel, Olivier Trédan, Ian F. Tannock
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Christopher M. Stephenson, Robert D. Levin, Thomas Spector, Christopher G. Lis
miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1
Jie Wang, Ke Sai, Fu-rong Chen, Zhong-ping Chen
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors
Hoai-Thu Thai, Christine Veyrat-Follet, France Mentré, Emmanuelle Comets
Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry
T.-H. Lin, K. Hu, J. Flarakos, M. Sharr-McMahon, J. B. Mangold, H. He, Y. Wang
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
Atish Patel, Amit K. Tiwari, Eduardo E. Chufan, Kamlesh Sodani, Nagaraju Anreddy, Satyakam Singh, Suresh V. Ambudkar, Ralph Stephani, Zhe-Sheng Chen
Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience
Jae-Cheol Jo, Myoung Joo Kang, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Gyungyub Gong, Hak Hee Kim, Seung Do Ahn, Su Ssan Kim, Byung Ho Son, Sei Hyun Ahn, Sung-Bae Kim
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography
Gakuji Osawa, Kazuhiko Yoshimatsu, Hajime Yokomizo, Sachiyo Okayama, Masano Sagawa, Yoshihiko Naritaka
Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer
Katsushi Takebayashi, Eiji Mekata, Hiromichi Sonoda, Tomoharu Shimizu, Yoshihiro Endo, Tohru Tani
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis
Jun Ho Ji, Se Hoon Park, Jeeyun Lee, Tae Won Kim, Yong Sang Hong, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Hye Jin Kang, Sang Joon Shin, Byoung Yong Shim, Young Suk Park
Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
Peter L. Bonate, A. Benjamin Suttle
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
T. H. Han, R. Chen, R. Advani, R. B. Berryman, S. E. Smith, A. Forero-Torres, J. D. Rosenblatt, M. R. Smith, J. Zain, N. N. Hunder, A. Engert
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells
Huaping Liu, Metin Kurtoglu, Yenong Cao, Haibin Xi, Rakesh Kumar, Jeffrey M. Axten, Theodore J. Lampidis
A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder
Zeynep Eroglu, John P. Fruehauf
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma
Satoshi Noda, Makoto Shioya, Daiki Hira, Yoshihide Fujiyama, Shin-ya Morita, Tomohiro Terada
Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view
Maria Isabel Mas-Fuster, Amelia Ramon-Lopez, Ricardo Nalda-Molina
Erratum to: Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
Gangjun Du, Yiming Yang, Yaping Zhang, Ting Sun, Weijie Liu, Yingying Wang, Jiahuan Li, Houyun Zhang